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 Abstract:  
Background: Tumours are no longer regarded as isolated masses of aberrantly proliferating epithelial 
cells. Rather, their properties depend on complex interactions between epithelial cancer cells and the 
surrounding stromal compartment within the tumour microenvironment. In particular, leukocyte 
infiltration plays a role in controlling tumour development and is now considered one of the hallmarks 
of cancer. Thus, in the last few years immunotherapy has become a promising strategy to fight cancer, 
as its goal is to reprogram or activate anti-tumour immunity to kill tumour cells, without damaging the 
normal cells and provide long-lasting results where other therapies fail. However, the immune-related 
adverse events due to the low specificity in tumour cell targeting, strongly limit immunotherapy 
efficacy. In this regard, nanomedicine offers a platform for the delivery of different 
immunotherapeutic agents specifically to the tumour site, thus increasing efficacy and reducing 
toxicity. Indeed, playing with different material types, several nanoparticles can be formulated with 
different shape, charge, size and surface chemical modifications making them the most promising 
platform for biomedical applications. 
Aim: In this review, we will summarize the different types of cancer immunotherapy currently in 
clinical trials or already approved for cancer treatment. Then, we will focus on the most recent 
promising strategies to deliver immunotherapies directly to the tumour site using nanoparticles. 
Conclusions: Nanomedicine seems to be a promising approach to improve the efficacy of cancer 
immunotherapy. However, additional investigations are needed to minimize the variables in the 
production processes in order to make nanoparticles suitable for clinical use. 
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1. INTRODUCTION 
Bidirectional communication between cells and their 
microenvironment is critical for both normal tissue 
homeostasis and tumour growth. In particular, growing 
evidence has supported the idea that the immune system 
plays a crucial role in initiation, progression and tumour 
development and the presence of immune cells within the 
tumour microenvironment (TME) is now considered as a 
hallmark of cancer [1,2].  
 
Dr. Alessandra Iscaro, Department of Oncology & Metabolism, University 
of Sheffield, Medical School, Beech Hill Road, Sheffield, UK. Tel: +44 (0) 
114 215 9080. Email: a.iscaro@sheffield.ac.uk 
Dr. Munitta Muthana, Department of Oncology & Metabolism, University 
of Sheffield, Medical School, Beech Hill Road, Sheffield, UK. Tel: +44 (0) 
114 215 9057. Email: m.muthana@sheffield.ac.uk 
Thus, cancer is a complex disease that often requires 
multiple traditional treatments that target tumour cells, 
however in the last few decades there has been a surge in 
therapies that target or activate the immune response in 
cancer [3]. Indeed, the goal of cancer immunotherapy is to 
engage the immune system to attack and kill tumour cells 
specifically, without damaging the normal cells [2]. 
Different types of immunotherapy have been developed in 
the last few years [3,4]: for instance, the genetic 
reprogramming of immune cells in order to kill cancer cells, 
i.e. chimeric antigen receptor (CAR)-T cell therapy, the use 
of cytokines to modulate the immune response or the use of 
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monoclonal antibodies (mAbs) against specific antigens 
(Ags) expressed on tumour surfaces, such as anti-PD-L1 
mAbs [3-5]. In addition, oncolytic virotherapy is an 
emerging strategy traditionally known for its oncolytic 
action on tumour cells, and it is increasingly being 
recognised for its ability to boost the immune response 
against cancer [6,7]. Despite these advancements, cancer 
immunotherapy still has some challenges and full potential is 
not being achieved with respect to efficacy and immune-
related adverse events (IRAEs) [8]. Thus, the current efforts 
are focusing on further developments to enhance specificity, 
effectiveness and reduce toxicity. A promising strategy for 
increasing the specificity of tumour immunotherapy is 
nanomedicine. Indeed, due to their small sizes, nanoparticles 
(NPs) can cross cell and tissue barriers, protect bioactive 
molecules and overcome poor drug distribution and lack of 
selectivity, making them a favourable material for 
biomedical applications [9,10]. In this review article, we will 
provide a general overview on the different types of 
immunotherapies and then we will focus on the most 
promising strategies to deliver immunotherapeutic agents 
directly to the tumour site through the use of nanomedicine. 
2. Immune cells in cancer 
The presence of leukocytes within tumours, observed in the 
19th century by Rudolf Virchow, provided the first 
indication of a possible link between inflammation and 
cancer [11]. Nowadays, a role for inflammation in 
tumourigenesis is generally accepted, and it has become 
evident that an inflammatory microenvironment is an 
essential component of all tumours, including some in which 
a direct causal relationship with inflammation is not yet 
proven. The hallmarks of cancer-related inflammation 
include the presence of inflammatory cells and inflammatory 
mediators (for example, chemokines, cytokines and 
prostaglandins) in tumour tissues, tissue remodelling and 
angiogenesis, similar to those seen in chronic inflammatory 
responses and tissue repair [12]. Immune cells in the TME 
include both innate and adaptive immune cells. For instance, 
T cells have been found in the TME of various tumour types, 
they are called tumour-infiltrating lymphocytes (TILs) and 
are considered to play a decisive role in tumour initiation and 
progression [13]. TILs can have both pro- and anti-tumour 
activity: indeed, for example, CD4+ Thelper (Th)1, CD8+ T 
and natural killer (NK) T cells inhibit tumour growth by 
producing interferon gamma (IFNγ) that in turn activates 
tumouricidal macrophages for the phagocytosis of cancer 
cells. Activated macrophages also produce interleukin (IL)-
12 that promotes Th1 cell differentiation, establishing a 
tumour-suppressing feedback loop [14]. T cell-released IFNγ 
is also responsible for stimulating the antigen presenting 
cells (APCs) that then activate the CD8+ cytotoxic T cells in 
order to promote tumour cells lysis. Moreover, most tumours 
are positive for MHC class I, but negative for MHC class II 
and cytotoxic CD8+ cells are able to induce tumour killing 
upon direct recognition of peptide antigens, presented by the 
tumour’s MHC class I molecules [15]. In contrast, some 
studies show that Th2 and T regulatory (Treg) cells have a 
pro-tumoural function. For instance, Th2 cells release IL-4, 
IL-5, IL-10, and IL-13 that induce anergy of T-cells and loss 
of cytotoxicity [16,17]. Since Tregs inhibit the activation of 
both CD4+ and CD8+ T cells, within the TME they are 
considered to have a pro-tumoural activity by suppressing 
anti-cancer cell immunity. Indeed, transforming growth 
factor beta (TGFβ) secreted by Tregs may suppress IFNγ 
production by Th1 and CD8+ T cells, while also promoting 
the generation of Foxp3+ Tregs and differentiation of Th17 
cells, which, when taken together, likely favours the growth 
and progression of cancer [15-17]. In addition, myeloid 
derived suppressive cells (MDSCs) are a heterogeneous 
group of immature myelomonocytic cells that are 
functionally defined by their potent immunosuppressive 
activity on T cells. Indeed, they express several enzymes 
such as arginase-1 (ARG-1) and indoleamine 2,3 
dioxygenase (IDO) causing arginine, tryptophan and 
cysteine depletion in the TME. This situation causes 
inefficient T cell receptor complex formation and then 
proliferative arrest of Ag-activated T cells [18-20]. 
Moreover, MDSCs produce reactive oxygen species (ROS), 
nitric oxide (NO), TGFβ and IL-10 that suppress anti-
tumoural immunity [21,22]. Macrophages are other crucial 
players in cancer progression: in response to different 
signals, they undergo polarized activation: the ‘classically’ 
activated (M1) and the ‘alternatively’ activated (M2) 
macrophages. M1 macrophages have tumouricidal activity as 
they produce high amounts of inflammatory cytokines, ROS 
and activate the immune response [23,24]. On the other 
hand, M2 macrophages promote tissue repair and 
angiogenesis, and favour tumour progression [25-27]. 
Although tumor-associated macrophages (TAMs) are 
generally described as an M2-like population, evidence 
suggests that M1/M2 classification is blurred as, especially 
in vivo, M1-like phenotype often overlaps with 
inflammatory and immunosuppressive features [28,29]. 
Other molecules that take part to the immunosuppression 
observed in the TME are the immune checkpoint proteins 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and 
Programmed Death 1 (PD-1) that are both expressed by 
activated T cells. CTLA-4 binds CD80 and CD86 (on the 
surface of APCs) with greater affinity and avidity than CD28 
and transmits an inhibitory signal to T cells [30]. Similar to 
CTLA-4, PD-1 has been shown to block effector T cell 
activation and functions, upon the interaction with its ligands 
PD-L1 or PD-L2 [30]. Accordingly, overexpression of PD-
L1 and CTLA-4 has been observed on the surface of tumour 
cells in several types of cancer [31]. At present it is generally 
accepted that immune response can inhibit tumour growth in 
the early stage of cancer development through a process 
called immune-editing. However, in advanced state of 
tumour progression, cancer cells promote an 
immunosuppressive microenvironment that inhibits anti-
tumour immunity. Indeed, studies in murine models from the 
lab of Robert Schreiber have suggested the “Three Es of 
cancer immune-editing”: the interplay between tumour and 
the immune system goes through three phases characterized 
by immune-elimination (of cancer cells), immune-
equilibrium (between cancer cells and cells of the immune 








During the elimination phase, cells of the innate immune 
system recognize the presence of a growing tumour that has 
undergone stromal remodelling, causing local tissue damage. 
This is followed by the induction of inflammatory signals 
essential for recruiting cells of the innate immune system 
(e.g. NK cells, NKT cells, macrophages and dendritic cells 
(DCs)) to the tumour site. During this phase, the infiltrating 
lymphocytes are stimulated to produce IFNγ promoting 
cancer cell death. Tumour cell debris is then ingested by 
DCs, followed by the migration of these cells to the draining 
lymph nodes. The recruitment of more immune cells also 
occurs and it is mediated by the chemokines produced during 
the inflammatory process. In the draining lymph nodes, 
tumour-loaded DCs trigger the differentiation of Th1 cells 
that in turn facilitates the development of cytotoxic CD8+ T 
cells. In the final phase of elimination, tumour-specific 
CD4+ and CD8+ T cells home to the tumour site and the 
cytotoxic T lymphocytes then destroy the Ag-bearing tumour 
cells. Tumour cell variants that have survived the elimination 
phase enter the equilibrium phase. In this phase, 
lymphocytes and IFNγ exert a selection pressure on tumour 
cells that are genetically unstable and rapidly mutating. 
Tumour cells that have acquired resistance to elimination 
continue to grow and expand in an uncontrolled manner and 
modulate the TME promoting the activity of 
immunosuppressive cells in order to evade the immune 
response and thus, leading to malignancy [32,34]. Since 
some cancers progress faster and reach the escape phase 
earlier than others, it could be speculated that the quality and 




influenced by numerous factors in the TME: for instance, 
cytokines and chemokines determine the cell types attracted, 
but also the availability of oxygen and nutrients could 
influence the immune response and functions [34].  
3. Cancer Immunotherapy 
As mentioned above, inflammation is a hallmark of cancer 
and even if the immune system acts against cancer cells, 
tumours can escape from immune attack [32-34]. For this 
reason, in the last few years, many studies have been 
conducted with the aim of trying to enhance the activity and 
functions of anti-tumoural immune cells, paving the way to 
the development of cancer immunotherapy [3-5]. This is the 
modulation and use of the patient’s own immune system to 
target cancer cells. In that manner, cancer immunotherapy 
focuses on developing agents that activate or enhance the 
immune system’s recognition and killing of the tumour cells 
[35,36]. This section will summarize the main strategies and 
the most recent advances in the field of immunotherapy for 
the treatment of tumours, in particular, highlighting the 
immunotherapeutic agents already approved for clinical use 
by the Food and Drug Administration (FDA) or in clinical 
trials (Table 1). 
3.1 Cell-based immunotherapy and vaccines 
Cellular immunotherapy is an innovative treatment approach 
that harnesses the body’s own immune system to fight 
cancer. It consists of manipulation or stimulation of 

































Figure 1. The immune-editing process – elimination, equilibrium, and escape.  The interplay between tumour and the 
immune system goes through three phases characterized by immune-elimination (of cancer cells), immune equilibrium 
(between cancer cells and cells of the immune system) and immune escape (by cancer cells). 
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cells and in the past few years it has attracted much research 
and clinical trial interest [36]. In particular, many studies 
have focused on the role of DCs as they have the unique 
function to act as APCs for T cell activation and thus, for the 
stimulation of the immune response against a specific Ag, 
providing a crucial link between both innate and adaptive 
immune responses. These features allow DCs to be 
considered as a target for the development of therapies that 
can induce immune responses and anti-tumour activity [37-
39]. DC-based immunotherapy approaches can be employed 
in a couple of ways:  i) the direct in vivo DC targeting to 
enhance their anti-cancer phenotype and ii) the ex vivo DC 
stimulation in order to infuse them back into the host for 
carrying out anti-cancer effector function [40]. Several 
strategies for the in vivo DC targeting have been developed 
in the last few years [41,42]. For instance, it has been 
demonstrated that tumour Ag-conjugated antibodies (Abs) 
against a variety of molecules primarily expressed on DCs 
such as DEC-205, CD11c and Clec9A could prevent or 
inhibit tumour growth in a mouse model of melanoma and 
breast cancer [42,43]. Indeed, immunization with tumour-Ag 
anti-DEC-205 or anti-Clec9A monoclonal Abs (mAbs) 
induced delayed cancer growth in melanoma-bearing mice 
[44-47]; while a decreased in tumour development was 
observed in mice immunized with anti-CD11c mAb in a 
model of murine breast cancer [48]. Although these results 
are promising, most of these mAbs are still in preclinical 
phase with only the anti-DEC-205 Ab undergoing a phase I 
clinical trial. Indeed, in this study, the anti-DEC-205-NY-
ESO-1 fusion protein, CDX-1401, has been given 
intravenously in combination with decitabine and nivolumab 
in patients with myelodysplastic syndrome (MDS) or low 
blast count acute myeloid leukaemia (AML) in order to help 
the immune system to specifically target and kill cancer cells 
(https://clinicaltrials.gov/ct2/show/NCT03358719). 
Alternatively, as circulating DCs constitute only about 1% of 
peripheral blood mononuclear cells (PBMCs), several ways 
to generate them from precursors have been investigated for 
DC vaccination purposes [15]. Indeed, DCs can be generated 
from CD34+ progenitor cells or monocytes by stimulation 
with IL-4 and granulocyte-macrophage colony-stimulating 
factor (GM-CSF). Then, DCs are loaded with tumour-
associated Ags and administered to the patient [39,49]. 
Recently, a DC-based vaccine (Sipuleucel-T; Dendreon) was 
approved for the treatment of advanced prostate cancer 
[50,51]. The development of Sipuleucel-T is based on the 
concept that patient’s isolated DCs are incubated ex vivo 
with recombinant fusion protein Ag, which contains both the 
antigen prostatic acid phosphatase (PAP), an enzyme highly 
expressed by prostate cancer cells, and GM–CSF. Once 
activated, Ag-loaded DCs are infused back into the patient 
and are able to fight prostate cancer cells by activating an 
immune response against them [49,52]. As Sipuleucel-T was 
tested in phase III trials and induced a survival benefit [53-
55], DC-based vaccines seem to be a promising solution for 
effective cancer therapy. Other promising results have been 
obtained by the use of CAR-T cell therapy. This a new 
strategy that consists of the transduction of patient’s isolated 
T cells with chimeric antigen receptors (CARs) that bind to 
specific ligands on cancer cells. These modified T cells are 
then amplified and infused back into the patient where they 
can attack cancer cells [37,56]. One of the first clinical trials 
using CAR-T cells was reported by Kalos and colleagues, 
showing that CAR-T cells targeting B cells in chronic 
lymphocytic leukaemia (CLL) were able to induce complete 
remission in two of three patients included in the study [57]. 
Recently, many clinical trials of CAR-T cells have been 
completed for the treatment of B-cells malignancies, such as 
Kymriah (tisagenlecleucel; Novartis) and Yescarta 
(axicabtagene ciloleucel; Kite Pharma) that were approved 
by the FDA in August and October 2017, respectively [59-
61]. However, CAR-T cell therapy against solid cancers 
have shown less specificity and efficacy compared to liquid 
tumours, probably due to the lack of a specific target and 
promising results have been obtained only in neuroblastoma 
and sarcoma patients [57,60,61]. Moreover, several studies 
have indicated that NK cells are frequently deficient or 
dysfunctional in patients with malignancy, indicating that 
this may be a key factor in cancer immune-evasion and 
progression. In addition, their rapid killing and broad 
cytotoxicity make NK cells uniquely primed for use in 
adoptive therapy. For these reasons, potentiating NKs 
against tumour cells is an encouraging approach in cancer 
immunotherapy [62]. In this regard, several strategies for the 
ex vivo NK cells expansion have been evaluated in the last 
few years: for instance, the company Miltenyi Biotec has 
developed a protocol to expand peripheral NK cells from 
irradiated autologous PBMCs, used as feeder cells, in the 
presence of NKs activating molecules, such as the anti-CD16 
mAb, in order to provide a suitable environment for the NK 
cells expansion. [63-65], while the company Glycostem 
enabled a system to expand NKs from umbilical cord blood 
stem cells and they have been shown to be effective and safe 
in a phase I clinical trial in elderly AML patients [63,66]. 
However, these approaches are very personalized and 
expensive and thus, it may not be possible to apply them to 
most of the patients.  
3.2 Immune checkpoints inhibitors 
Unfortunately, the immunosuppressive TME often 
compromise the therapeutic effects of cell-based 
immunotherapy, as cancer cells are able to evade the 
immune system by inducing nutrient depletion and activating 
negative immune regulatory pathways, thus impairing anti-
tumour immune cell functions and promoting the activity of 
immunosuppressive Tregs and MDSCs [22,67]. For instance, 
it has been demonstrated that molecules usually expressed on 
activated T cells, such as the immune checkpoint proteins 
CTLA-4 and PD-1 play a crucial role in the 
immunosuppression observed in the TME [60-70]. As 
mentioned above, PD-1 has been shown to suppress effector 
T cell activation and functions, upon interaction with its 
ligands, PD-L1 or PD-L2. Likewise, CTLA-4 binding to 
CD80 and CD86, expressed on APCs, transmits an inhibitory 
signal to T cells [30]. Recent evidence has shown PD-L1 and 
CTLA-4 upregulation on the surface of tumour cells in 
several types of cancer [31] and for this reason, in the last 
few years, mAbs targeting CTLA-4, PD-1, PD-L1 or PD-L2 
have been developed and tested in clinical trials for the 
treatment of several types of cancers [67,70-72]. Among the 
mAbs against CTLA-4, Ipilimumab (Yervoy; Bristol-Myers 





Immunotherapy Drug name Mechanism Phase Tumour type References 
DC-based Vaccine Sipuleucel-T Patients’ APCs activated 






CAR-T cell therapy Kymriah Patient’s T cells are 
engineered to target a 







CAR-T cell therapy Yescarta Patient’s T cells are 
engineered to target a 






NK cell therapy oNKord NKs generated ex vivo 
from umbilical cord 






ICI  Ipilimumab Anti-CTLA-4 mAb Approved 
by FDA 
Unresectable or MM [72-79] 
ICI Nivolumab Anti-PD-1 mAb Approved 
by FDA 
NSCLC, MM, HL, 
SCCHN, MUC 
[80,82,84,86] 
ICI Pembrolizumab Anti-PD-1 mAb Approved 
by FDA 
NSCLC, MM, HL, 
SCCHN, MUC 
[81,83,85,87] 
ICI Durvalumab Anti-PD-L1 mAb Approved 
by FDA 
MUC [89] 





ICI Atezolimumab Anti-PD-L1 mAb Approved 
by FDA 
NSCLC, MUC [88] 




Lymphomas and solid 
cancers 
[72,93] 





Cytokine Roferon-A IFNα2a Approved 
by FDA 
HCL, CML [100,101] 





myeloma, HCL, CIN 
[100,101] 
Oncolytic virus T-Vec  
(Herpes simplex 
virus) 
Tumour oncolysis and 
since virus is armed with 
GM-CSF this leads to 
recruitment of APCs 
Approved 
by FDA 
Advanced melanoma [38,103,108] 
Oncolytic virus JX-594 
(vaccinia virus) 




Melanoma, HCC [113,114] 
Oncolytic virus CG0070 
(Adenovirus) 
Tumour oncolysis (viral 
replication under the 






Oncolytic virus Reolysin 
(Reovirus) 
Tumour oncolysis 
(viral replication under 







Table 1. Main immunotherapeutic agents approved by the FDA or in clinical trial for cancer treatment. 
ICI= Immune checkpoint inhibitor; NSCLC=non-Small Cell Lung Carcinoma; MM= Metastatic Melanoma; HL= Hodgkin 
Lymphoma; SCCHN= Squamous Cell Carcinoma of Head and Neck; MUC= Metastatic Urothelial Carcinoma; FL= 
Follicular Lymphoma; HLC= Hairy Cell Lymphoma; CIN= Cervical Intraepithelial Neoplasms; HCC= Hepatocellular 
Carcinoma. 
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Squibb) is worthy of a mention as it was one of the first 
immunotherapies to be approved by the FDA for the 
treatment of unresectable or metastatic melanoma 
(https://www.cancer.gov/about-cancer/treatment/drugs/fda-
ipilimumab) [72-79]. Since that time, several mAbs have 
been tested in clinical trials or have been approved for the 
treatment of different malignancies: i.e. both Nivolumab 
(Opdivo; Bristol-Myers Squibb) and Pembrolizumab 
(Keytruda; Merck and Co.) target PD-1 and have been 
approved for the treatment of metastatic non-small cell lung 
carcinoma (NSCLC), metastatic melanoma, classical 
Hodgkin lymphoma, squamous cell carcinoma of head and 
neck (SCCHN) and metastatic urothelial carcinoma [80-87]. 
Moreover, Durvalumab (Imfinzi; AstraZeneca UK Limited), 
Avelumab (Bavencio; EMD Serono, Inc.) and Atezolizumab 
(Tecentriq; Genentech Oncology), all of which target PD-L1, 
have been approved for the treatment of metastatic urothelial 
carcinoma, metastatic Merkel cell carcinoma and metastatic 
NSCLC, respectively [88-90]. However, only a low fraction 
of patients respond to immune checkpoint inhibitors due to 
primary or acquired resistance mechanisms, as recently 
reviewed by Vanpouille-Box C. and colleagues [72]. Thus, 
in the last few years, considerable attention has been 
attracted by mAbs that target co-inhibitory receptors other 
than CTLA-4 and PD-1, including V-set immunoregulatory 
receptor (VSIR, best known as B7-H5 or VISTA) with the 
aim of co-targeting different immune checkpoint molecules 
[91,92]. Indeed, the biotech company Curis is now testing in 
a phase 1 clinical trial a novel oral small molecule, also 
known as CA-170, dual inhibitor of immune checkpoints 
PD-L1/PD-L2 and VISTA for the treatment of advanced 
solid tumours or lymphomas 
(https://clinicaltrials.gov/ct2/show/NCT02812875) [72,93]. 
3.3 Cytokines therapy 
As mentioned above, cancer cells are able to communicate 
with the other components of the TME, shaping and 
manipulating the surrounding microenvironment to produce 
cytokines, growth factors and metabolites to meet their own 
needs [2,94,95]. In particular, deregulated cytokines 
production and aberrant cytokine signalling can lead to 
altered cell growth, differentiation and apoptosis as well as 
the secretion of factors that foster cancer progression and 
immune evasion [96,97]. Indeed, cytokines are major 
regulators of the innate and adaptive immune system 
allowing cells to communicate over short distances in a 
paracrine and autocrine manner and controlling leukocyte 
proliferation, differentiation, effector functions and survival 
[98]. Thus, recently, cytokines have been explored in the 
treatment of cancer in order to enhance anti-tumoural 
immunity [99,100]. However, only three cytokines have 
been approved so far by the FDA for use in cancer patients:  
recombinant interleukin IL-2 (Proleukin; Chiron) and two 
variants of recombinant interferon alpha 2 called IFNα2a 
(Roferon-A; Roche) and IFNα2b (Intron-A; Merk & Co). IL-
2 acts as a T- cell growth factor during the initiation of the 
immune response, and has a crucial role in terminating T-cell 
responses for the maintenance of self-tolerance, while IFNα 
belongs to the family of type I IFNs and, even if it has anti-
viral properties, recently it has also been linked to the 
pathogenesis of infectious disease, inflammatory disorders, 
autoimmune diseases and cancers [100]. Proleukin has been 
approved for the treatment of metastatic melanoma and renal 
cell carcinoma (RCC), Roferon-A for the treatment of hairy 
cell lymphoma (HCL) and chronic myelogenous leukaemia 
(CML), while Intron-A has been approved for the use in 
patients with AIDS-related Kaposi's sarcoma, melanoma, 
follicular lymphoma (FL), multiple myeloma MM, HCL and 
cervical intraepithelial neoplasms (CIN) [100,101]. In 
addition, several clinical trials have been carried out to 
evaluate the use of IL-15, IL-12, IL-21 or GM-CSF for the 
treatment of melanoma and renal cell cancer. However, 
regardless of their promising results in murine models, these 
cytokines showed inconsistent results in humans together 
with several side effects and thus require further clinical 
evaluation [100,102].  
3.4 Oncolytic viruses 
Oncolytic viruses (OVs) represent a new class of therapeutic 
agents that promote anti-tumour responses through a dual 
mechanism of action that is dependent on selective tumour 
cell killing and the induction of systemic anti-tumour 
immunity. Specifically, viral replication in cancer cells, 
followed by cancer cell lysis, results in the release of more 
viruses, as well as tumour Ags. Consequently, Ag uptake by 
APCs indirectly promotes both innate and adaptive immune 
responses [38, 103-105]. In addition to these important 
properties, OVs are considered very flexible agents as they 
can be genetically engineered to further enhance anti-tumour 
activity and, thus, to maximize their features. Indeed, for 
instance, the capsid of OVs that do not have an innate 
tropism for cancers can be engineered to enhance virus 
binding to tumour cell receptors [103,106,107]. Moreover, 
other strategies to improve selective replication in cancer 
cells are the deletion/insertion of tissue- or cell type- specific 
promoters to induce gene expression in tumour cells [108]; 
or the placement of viral genes under the control of tissue 
specific elements. For instance, Ad[I/PPT-E1A] is a new OV 
that specifically replicates in prostate cancer cells as the 
adenovirus early region 1 (E1A) is under the control of three 
prostate specific elements, such as the prostate-specific 
antigen (PSA) enhancer, the prostate-specific membrane 
antigen (PSMA) enhancer and the T-cell receptor gamma-
chain alternate reading frame protein (TARP) promoter 
[108]. Therefore, these features allow OVs to be considered 
as a promising strategy for cancer immunotherapy. 
Consequently, several OVs are currently being tested in 
clinical trials as anti-cancer agents and in 2015 the 
Talimogene laherparepvec (T-Vec; Amgen Inc.) was 
approved by the FDA as the first OV for the treatment of 
advanced melanoma [38,109]. This attenuated herpes 
simplex virus (HSV) is engineered to preferentially replicate 
in cancer cells and to express the immune-modulatory 
cytokine GM-CSF which in turn, promotes APCs 
recruitment to the TME, thereby inducing the anti-tumour 
immunity [38,103,108]. In the phase III OPTiM clinical trial 
for treating advanced melanoma, T-Vec treatment showed 
extended durable response rates and prolonged median 
overall survival compared with GM-CSF alone, with 
minimal adverse effects, highlighting the fact that these 
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agents can be safely used in a clinical setting [110-112]. 
Based on these promising results, several OVs are currently 
being tested in clinical trials: i.e. in early phase I studies, JX-
594, a genetically engineered thymidine kinase-mutant/GM-
CSF expressing Vaccinia virus (VAC), demonstrated highly 
promising results in patients with melanoma [113] and 
hepatocellular carcinoma (HCC) [114]. In addition, CG0070 
is a GM-CSF expressing adenovirus where the E1A gene is 
under the control of E2F, a retinoblastoma (Rb)-dependent 
transcription factor, providing selectivity for cells with an 
abnormal p16/Rb pathway [115]. CG0070 has selective 
replication, cytotoxicity, production of GM-CSF and anti-
tumour efficacy in urothelial carcinoma and a human phase I 
trial of intravesical administration of CG0070 included 35 
patients with non-muscle invasive urothelial cancer [116] 
showed that the therapy was well tolerated; however, the 
cohort of patients was too small for definitive conclusions 
[117]. Among reoviruses (RVs), Reolysin (Pelareorep; 
Oncolytics Biotech Inc.) has been extensively evaluated in 
preclinical models and clinical studies for the treatment of 
solid tumours and haematological malignancies [118,119]. 
Reolysin replicates in and eventually kills Ras-activated 
tumour cells, and as cell death occurs, progeny virus 
particles are then free to infect surrounding cancer cells until 
all tumour cells carrying an activated Ras pathway are 
destroyed [120]. In April 2015, the FDA granted orphan 
drug designation to Reolysin for malignant glioma [121] and 
in May 2017, the FDA granted fast track designation for 
Reolysin in metastatic breast cancer [122]. 
3.5 Immunotherapy challenges 
Despite all the advances described above, obstacles still exist 
in cancer immunotherapy and the efficacy of this treatment 
has been limited. Indeed, immunotherapy seems to work 
only for some patients and types of tumours, and some 
patients acquire resistance and relapse after a period of 
response [123]. Therefore, there is the need to develop new 
strategies to overcome resistance and to boost the immune 
system against cancers, especially for the patients with little 
or no infiltrating immune cells [4,124]. Moreover, one of the 
main problems of cancer immunotherapy is that it is often 
associated with mild-to-severe toxicities and autoimmune 
diseases due to anomalous and general immune activation 
[125]. Indeed, several studies have shown that cancer 
immunotherapy is associated with IRAEs such as, 
inflammatory skin disorders, thyroid dysfunctions, 
hypophysitis, type 1 diabetes mellitus, hepatotoxicity, 
gastrointestinal, neurological, cardiac, rheumatologic and 
renal toxicities. These problems are often due to the non-
specific delivery of the immunotherapeutic agents that can 
target also healthy tissues, resulting in adverse events with 
low drug delivery to the tumour site [126-128]. Moreover, 
the presence in the TME of immunosuppressive cells, such 
as MDSCs and Tregs, results in the increased production of 
immunosuppressive cytokines (e.g., IL-10, TGFβ) that 
together with the low immunogenicity of tumour Ags 
strongly limits the anti-tumour response elicited by 
immunotherapies [127]. Therefore, to overcome these 
problems we need to develop new strategies for delivering 
an optimal amount of immunotherapy to a specific site, with 
appropriate kinetics and dosing schedule, without inducing 
deleterious side effects. A possibility could be the 
combination of different therapies to obtain differential 
targeting within the TME, such as the concomitant increase 
of Ag presentation by APCs and T-cell activation, together 
with the induction of cancer cell death or the targeting of 
other stromal components of the TME [128]. However, 
obtaining these achievements is complicated and an easier 
and more promising approach could be the use of 
nanomedicine. In fact, in the case of systemic administration 
of drugs, NPs can better protect the therapeutic agent from 
its clearance, thus offering a platform that can help the 
specific delivery of immunotherapeutic agents to the tumour 
site, thus reducing their adverse events. Indeed, NPs can 
protect bioactive molecules and can be engineered to modify 
their size and shape, immunogenicity, biodistribution, site-
specific targeting, therapeutic loading and detectability by 
medical imaging [10,129]. All these features allow NPs to 
become promising candidates for the delivery of cancer 
immunotherapies and will be discussed in the following 
sections. 
4. Nanoparticles properties 
In general, NPs are divided into different categories based on 
their physical and chemical properties such as material type, 
size, shape, charge and surface chemical modifications, and 
it is now well accepted that all these features play an 
important role in their kinetics of internalization, bio-
distribution, cellular uptake, immunogenicity and loading 
efficiency [10,127]. For instance, various materials have 
been experimented for biomedical applications including 
lipids, metals, polymers, carbon structures and inorganic 
materials that can be used for NP formulation and all of them 
have different features. In particular, polymers such as 
poly(lactic-co-glycolicacid) (PLGA) or chitosan have been 
shown to increase NP immunogenicity by supporting DC 
maturation and thus enhancing immune responses [10,131]. 
When considering immunogenicity, a component that is now 
generally used for NP formulation is the polyethylene glycol 
(PEG) polymer coating. In fact, PEG is well known for 
immune-camouflage properties as it reduces NP 
immunogenicity: PEGylation is generally believed to 
decrease complement activation responses and evade 
clearance by the immune system, thereby enabling longer 
NP circulation time [130]. Moreover, according to a general 
definition, NPs are defined as having dimensions below 
100nm; however, especially in the area of drug delivery, 
relatively larger NPs (size >100 nm) may be needed for 
loading a sufficient amount of drug onto the particles: for 
instance big oncolytic viruses, such as adenoviruses with a 
size around 90-100nm, have to be encapsulated inside larger 
NPs [9,129,130]. On the other hand, modifying the NP size 
could critically affect their clearance. For instance, it has 
been shown that NPs with a diameter smaller than 10 nm are 
generally cleared in the kidneys, while bigger NPs are 
usually cleared by the spleen and the liver [127,132]. In 
addition, NP size can interfere with their transport into the 
blood and their extravasation to a tumour or an inflammatory 
site. Indeed, at the tumour site, the large fenestrations present 
in the tumour vasculature could allow the extravasation also 
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of large NPs. This is due to the rapid cancer cell proliferation 
that promotes the formation of neovasculature for their 
nutritional and oxygen supply. These newly formed tumour 
vessels are usually abnormal in forms and architecture with a 
lack of smooth muscle layer and large fenestrations, 
facilitating NP accumulation within the tumours. This 
process is also known as the enhanced permeability and 
retention (EPR) effect and it is exploited for improving 
nanomedicine delivery to the tumour site [132-135]. 
However, the EPR effect can be limited by the presence of 
cancer cells and dense collagen fibres that cause extracellular 
matrix (ECM) stiffness and high interstitial fluid pressure. 
These circumstances act all together to trap NPs and obstruct 
their extravasation [132,133]. In this context, together with 
NP material type and size, also the shape can be a crucial 
factor for NP tissue permeation. For instance, Chauahn and 
colleagues showed that NP-tumour penetration is dependent 
on their shape. Indeed, comparing nanorods and nanospheres 
the authors found that nanorods exhibited superior transport 
and distribution into mammary tumours in vivo versus 
nanospheres of similar plasma half-life [136]. Moreover, it 
seems that cylindrical hydrogel NPs are more efficiently 
internalized by APCs, compared to rods and spherical NPs, 
therefore eliciting a stronger T cell activation and 
proliferation when injected subcutaneously in mice [137]. In 
addition, the nanodrug surface charge can affect NP cellular 
uptake and tissue permeation. For instance it has been shown 
that cationic NPs are easily taken up by DCs and 
macrophages, but can also be trapped by the negatively 
charged ECM reducing their tissue permeation compared 
with neutral and anionic carriers [10,138-140]. However, 
exploiting the EPR effect, the specific NP properties and the 
composition of the TME is not enough to deliver a sufficient 
drug amount at the tumour site. Therefore, passive nano-
targeting is not the best approach for drug delivery. A 
possible solution could be an active nano-targeting achieved 
by chemical modifications of the NP surface: this approach 
could allow a specific NP delivery to tumours together with 
a low nanocarries distribution in healthy tissues [141]. 
Indeed, targeting molecules can be linked to the NP surface 
with the aim of binding receptors expressed by tumour cells 
or by the surrounding microenvironment. The internalization 
of the complexes occurs by receptor-mediated endocytosis 
through the formation of the endosome and the subsequent 
fusion with the lysosome where the acidic pH allows the 
release of the drug inside the cell [141]. In this context, 
promising examples of receptors that can be actively targeted 
are the folate receptor, the epidermal growth factor receptor 
(EGFR), vascular endothelial growth factor receptors 
(VEGFR-1/2), integrins and matrix metalloproteinases 
(MMPs) that are usually overexpressed by cancer cells or by 
the surrounding stroma [141]. Therefore, NPs are a 
promising strategy to deliver immunotherapeutic agents and 
in the last few years many goals have been achieved in this 
field. Indeed, several immunotherapies such as monoclonal 
Abs, cancer vaccines, OVs, cytokines and peptides have 
been successfully conjugated to different types of NPs in 
order to stimulate anti-tumour immunity (Figure 2). Thus, in 
the next sections we will describe the most recent 
advancements in the nanodelivery of cancer 
immunotherapies.  
4.1 Lipid nanocarriers 
Examples of lipid nanocarriers are liposomes, solid-lipid 
NPs and phospholipids micelles. In particular, among them, 
liposomes are considered an ideal drug delivery system as 
they consist of spherical vesicles having one or more lipid 
layers containing an aqueous core, so that they can entrap 
both hydrophilic and lipophilic agents in the lipid layers or in 
the internal compartment, respectively [142,143]. Therefore, 
it is not surprising that in the last few years many studies 
have focused on the delivery of liposomes-encapsulated 
drugs. The first success in this context has been the 
liposome-encapsulated form of Doxorubicin (Doxil) 
approved by the FDA in 1995 for the treatment of ovarian 
cancer and AIDS-related Kaposi’s sarcoma [142-144]. This 
success paved the way for the use of liposomes for the 
delivery of several different drugs/agents also in field of 
cancer immunotherapy. For instance, in 2004 van 
Broekhoven et al. tried to target DCs through anti-DEC-205 
or anti-CD11c mAbs located on the surface of liposomes 
containing tumour Ags (B16 melanoma Ags or 
lipopolysaccharide), thus inducing potent anti-tumour 
immunity both in vitro and in vivo [145,146]. Moreover, 
lipid NPs have been used to improve CAR-T cell therapy 
against solid tumours. Indeed, as mentioned above, one of 
the main challenges of CAR-T cell therapy success in solid 
cancers is the presence of an immunosuppressive TME that 
can decrease the treatment efficacy [127] and in this context, 
the use of NPs could limit this obstacle. In fact, a recent 
study from Zhang and colleagues has shown promising 
results in a model of murine breast cancer. By the infusions 
of lipid NPs coated with the tumour-targeting peptide iRGD 
and loaded with a combination of a PI3K inhibitor to block 
immunosuppressive tumour cells activity and α-GalCer (an 
iNKT cell activator), the authors were able to switch the 
TME from immune- suppressive to stimulatory. This 
treatment created a therapeutic window of 2 weeks, enabling 
tumour-specific CAR-T cells to home to the tumour, 
undergo robust expansion and trigger tumour regression 
[147]. In addition, liposomes have been also used for 
improving cytokine therapy that is often associated with 
severe toxicities and failure in reaching the tumour site 
[100]. For instance, it has been demonstrated that, in a model 
of metastatic melanoma, the liposomal delivery of a 
stimulator of interferon genes (STING) agonist improves 
IFNγ production by tumour-associated APCs, leading to 
anti-tumour immunity enhancement and cancer regression 
compared to the free drug [148]. Another promising strategy 
that is now in a phase I/II clinical trial for advanced 
melanoma treatment is the use of lipoplexes (LPX). They 
protect a specific RNA from extracellular ribonucleases and 
allow its efficient uptake and expression of the encoded Ag 
by DCs and macrophages in various lymphoid 
compartments. The complexes trigger IFNα release by 
plasmacytoid DCs and macrophages promoting DC 
maturation in situ and anti-tumoural immune responses  
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demonstrated that anchoring anti-CD137 Ab and an 
engineered IL-2Fc fusion protein to the surfaces of 
PEGylated liposomes avoided toxicities and treated the 
majority of established primary tumours in the B16F10 
melanoma model compared to the equivalent intratumoural 
doses of soluble immunotherapeutic agent [151]. In addition, 
recently, a micelleplex made of an acid-activatable cationic 
micelle, a photosensitizer and a small interfering RNA 
(siRNA) was developed against PD-L1 in order to treat a 
B16-F10 murine melanoma tumour model. The micelleplex 
was activated only upon internalization in the acidic 
endocytic vesicles of tumour cells allowing the combined 
therapy to inhibit tumour growth and distant metastasis 
formation compared to photothermal therapy alone. These 
promising results strengthen the idea that the use of therapy 
combination together with NPs as delivery systems could 
strongly increase the efficacy of cancer immunotherapy 
[67,152]. Finally, also OV encapsulation inside lipid NPs is 
another strategy that needs to be mentioned as it has been 
shown encouraging results in the last few years. Indeed, 
Chen and colleagues have demonstrated that encapsulating 























Figure 2. NPs design strategy in cancer immunotherapy. NPs can be formulated and designed for potentiating 
immunotherapy efficacy, improving their specific delivery to the tumour site. They can be coated with immune checkpoints 
Abs, peptides and cytokines or can be loaded with OVs and Ags in order to boost the anti-tumour T cells for fighting cancer 
and escape from immunosuppressive mechanisms that could limit immunotherapy benefits. 
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reduces the OV neutralization by pre-existing Abs upon its 
systemic administration. Moreover, this complex efficiently 
inhibits HCC cell proliferation, induces apoptosis and 
enhances anti-tumour immunity in vivo [153]. In addition, in 
another study the authors showed that liposome-encapsulated 
plasmid DNA of telomerase-specific oncolytic adenovirus 
(TelomeScan) reduced production of adenovirus-neutralizing 
Abs upon intravenous administration into immune-
competent mice compared to the naked virus and had potent 
anti-tumour effects on colon carcinoma cells both in vitro 
and in vivo [154]. 
4.2 Polymeric nanoparticles 
Polymeric NPs are one of the most studied organic strategies 
for nanomedicine and some of them have been recently used 
for in vivo studies and clinical trials [67,155]. This is due to 
the fact that polymers are flexible and lightweight materials 
that can be produced at low cost. Moreover, they can be 
moulded for creating the desired structure and many of them 
are biodegradable and thus, less toxic [67,156]. For instance, 
PLGA is one of the most successfully used biodegradable 
polymer as its hydrolysis produces lactic acid and glycolic 
acid that can be easy metabolized by the cells through the 
Krebs cycle [157,158]. For this reasons, it is not surprising 
that in the last few years PLGA NPs have been extensively 
tested for improving cancer immunotherapy effects. Cruz 
and colleagues demonstrated that PLGA NPs encapsulated 
with tetanus toxoid (TT) peptide and ovalbumin (OVA) 
protein - as model Ags - in combination with the TLR7/8 
ligand R848 - as adjuvant - increase the kinetics of Ag 
delivery, processing, presentation, DC maturation and 
cytokines release, highlighting the idea that polymeric 
nanosystems could be used for fighting cancer [159]. In the 
context of cancer vaccines, it is also worth mentioning 
WDVAX: a phase I clinical trial for the treatment of 
melanoma 
(https://clinicaltrials.gov/ct2/show/NCT01753089). In 
particular, WDVAX consists of PLGA scaffolds loaded with 
melanoma Ags, GM-CSF and CpG, in order to activate DCs 
[160].  In the preclinical study, these scaffolds 
reprogrammed DCs to activate a robust immune response 
against murine B16F10 melanoma tumours. The authors 
showed that GM-CSF enhanced DC recruitment while CpG 
oligonucleotides (CpG-ODNs) – a TLR9 ligand - complexed 
to cationic polymer polyethylenimine (PEI) promoted DC 
activation in situ [160,161]. In another study, Hamdy et al. 
used PLGA NPs co-encapsulating the poorly immunogenic 
melanoma Ag, tyrosinase-related protein 2 (TRP2), together 
with a TLR4 ligand (7-acyl lipid A). NP-vaccinated mice 
showed TRP2-specific CD8+ T cell responses capable of 
mediating therapeutic anti-tumour response. More 
importantly, this vaccine strategy led to the reversal of 
immunosuppressive milieu within the TME, as evidenced by 
the increased levels of pro-inflammatory Th1 related 
cytokines (IL-2, IL-6, IL-12 and IFNγ) and the decreased in 
the levels of VEGF that is required for tumour growth [162]. 
PLGA is not the only polymer that has been used for drugs 
encapsulation: i.e., Li and colleagues used PEG-block-
poly(D,L-lactide) (PEG–PLA) NPs loaded with CTLA-4 
siRNA (siCTLA-4) and showed direct T cell activation both 
in vitro and in vivo. These NPs efficiently delivered the 
siCTLA-4 into T cells in vitro. Furthermore, they 
simultaneously increased in vivo the percentage of anti-
tumour CD8+ T cells and decreased Tregs cells among TILs, 
resulting in inhibition of tumour growth and prolonged 
survival time [163]. In addition, polymers have been also 
loaded with viruses. Indeed, it has been shown that PLGA 
microspheres can be used to encapsulate a PEGylated 
adenovirus, showing an increased stability and transfection 
efficiency in Hela cells compared to the naked virus, paving 
the way to the possibility of OV encapsulation also in 
smaller particles for cancer treatment [164].  
4.3 Inorganic Nanoparticles 
Inorganic NPs can be synthesized using metals, metal oxides 
and semiconductors such as silicon or ceramic. They have 
several advantages as they are relatively stable, easy to be 
synthetized, and can be easily loaded with enzymes, 
fluorochromes and magnets in order to facilitate their in vivo 
tracking [67,129]. One of the most employed type of 
inorganic NPs for biomedical applications are gold (Au)NPs 
that provide a versatile platform for the combination with 
oligonucleotides, Abs and proteins [165]. Therefore, it is not 
surprising that AuNPs have been studied for cancer 
treatment. For instance, recently, a nanomedicine platform 
called Aurimune has been developed. It consists of a 
colloidal gold NP covered with a PEG layer and coated with 
the tumour necrosis factor (TNF) molecule that selectively 
binds TNF receptors on blood vessel cells at the site of 
disease, causing blood vessel destruction and thus impairing 
tumour’s nutritional support structures and protective 
barriers. A phase I clinical trial in patients with advanced 
solid tumours has shown that recombinant human (rh)TNF, 
formulated as Aurimune, can be administered systemically at 
doses of rhTNF that were previously shown to be toxic and a 
phase II clinical trial to treat pancreatic cancer patients in 
combination with standard of care second line therapy has 
been announced 
(https://clinicaltrials.gov/ct2/show/NCT00356980). 
Moreover, other anti-cancer agents, such as IFNγ, have been 
successfully linked to the platform and need to be tested in 
clinical studies [166,167]. In the context of cell-based 
immunotherapy, Zhou et al. optimized a method to deliver 
the OVA peptide and CpG-ODNs to bone marrow derived 
DCs through the use of a nanoAu-cocktail consisting of both 
60nm and 80nm AuNPs [168]. Intravenously transfused 
nanoAu-cocktail pulsed DCs showed dramatically improved 
in vivo homing ability to lymphoid tissues and elicited an 
Ag-dependent CD8+ T cell response, indicating a potential 
use for cancer treatment [168]. Moreover, in another 
interesting study, AuNPs were functionalized with a red 
fluorescent protein as a model Ag, and CpG-ODN as a TLR9 
ligand for interaction with DCs within the lymph nodes, 
thereby strongly promoting a significant anti-tumour 
response in preclinical melanoma tumour models [169,170]. 
Mesoporous silica is another material used for preparing 
inorganic NPs, due to its high biocompatibility, and it has 
been shown to enhance anti-tumour immunity [67]. In this 
context, anti-CTLA-4 Abs have been encapsulated in 
functionalized mesoporous silica (FMS) NPs for the 
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treatment of mouse melanoma. It has been demonstrated that 
FMS-anti-CTLA-4 inhibited tumour growth [171]. 
Moreover, luminescent porous silicon NPs (LPSiNPs) have 
been used as carriers of FGK48, an agonistic anti-CD40 Ab, 
for APC stimulation and activation. These nanocomplexes 
had an intrinsic near infrared range (NIR) 
photoluminescence that served as a tracking indicator to 
study the interaction of the complexes with the immune 
system. Indeed, the authors showed that LPSiNPs 
successfully improved B cell activation by 30–40 fold by 
enhancing the expression of the activation markers CD86 
and MHC II [67, 172]. Iron oxide nanoparticles (Fe3O4 
NPs) have attracted broad interest due to their good 
biocompatibility, superparamagnetic properties and also 
because they have potential applications in many fields such 
as magnetic resonance imaging (MRI) that makes them 
promising for oriented delivery. Indeed, Fe3O4 NPs can be 
guided by an external magnetic field to concentrate in 
desired sites for targeted delivery and to help map their 
distributions [173]. In fact, a recent study from Cho and 
colleagues showed that Fe3O4 NPs covered with a photonic 
ZnO shell and loaded with carcinoembryonic Ag (CEA) are 
efficiently taken up by DCs within one hour and can be 
detected in vitro by confocal microscopy and in vivo by 
MRI. Furthermore, in a model of murine colon 
adenocarcinoma, mice immunized with DCs containing the 
NP-Ag complexes showed enhanced tumour Ag specific T-
cell responses, delayed tumour growth and better survival 
than controls [174]. Cruz and colleagues equipped 
superparamagnetic iron oxide particles (SPIO) with PLGA 
NPs recognizing DC receptors (e.g. the C-type lectin 
receptor CD209). MRI allowed tracking DCs - targeted with 
NPs carrying SPIO - within the lymph nodes where the 
authors also found an enhanced T cell proliferation [175]. In 
addition, another group recently used iron-dextran NPs 
functionalized with T cell MHC-peptides and anti-CD28 Abs 
to create artificial APCs for T cell expansion and activation. 
Upon the application of an external magnetic field, these 
artificial APCs aggregated and activated T cells which, in 
turn, were able to inhibit B16 melanoma in vivo growth 
[176]. In the context of immunecheckpoint inhibitors, 
Chiang et al. demonstrated that fucoidan-dextran-based 
magnetic NPs (IO@FuDex3) conjugated with an anti-PD-L1 
Ab and T-cell activators (anti-CD3 and anti-CD28) can 
switch the TME of a murine breast cancer model from 
immunosuppressive to anti-tumoural by TILs stimulation 
[177]. Attempts were also made to conjugate iron oxide NPs 
with OVs. An interesting study showed magnetic NPs 
conjugated with OV particles could be internalized by 
multiple cell lines and display a strong oncolytic activity. In 
addition, the complexes could be detected in vivo when 
administered in an intratumoural manner in an orthotopic rat 
hepatocellular carcinoma model [178].  
4.4 Magnetosomes 
Until recently, a biologically derived alternative to metallic 
particles, namely magnetosomes, has been relatively 
overlooked presumably due to the challenges associated with 
their biomanufacture [179,180]. Magnetosomes are 
functional magnetic NPs that are naturally generated by 
magnetotactic bacteria (MTB) and comprise a crystal of 
magnetite coated in a phospholipid membrane. They possess 
many advantages over chemically synthesized magnetic NPs 
including a narrow size and shape distribution and a 
biologically compatible surface chemistry, which prevents 
aggregation and provides an anchor for functional groups for 
biotechnology applications.  Medical applications in 
oncology have so far exploited the magnetic properties of 
magnetosomes for MRI contrast agents [181] and magnetic 
hyperthermia [182]. Indeed, magnetic hyperthermia is 
showing particular promise for hard to reach tumours 
including glioblastoma whereby 50% of mice inoculated 
with the GL-261 mouse glioma cell line were fully cured 5 
weeks post treatment (albeit using a subcutaneous model 
[183]) as well as 40% of mice bearing intracranial U87-Luc 
tumours [184]. Both studies observed only partial tumour 
coverage using nanoparticles and alluded to other 
mechanisms contributing to tumour cell destruction upon 
application of an alternating magnetic field (AMF) including 
tumour ischemia and/or enhancement of the antitumour 
immune response. Indeed, the heat shock protein HSP70 
expressed during hyperthermia induced necrotic cell death 
using magnetite cationic liposomes has been shown to 
suppress T-9 rat glioma in F344 rats [185] and boosting the 
immune response by heating tumours is a growing area with 
a number of review articles [186,187] (including 
mathematical models [188]). Recruitment for a clinical trial 
(NCT03393858) is also currently underway to investigate 
the clinical efficacy and toxicity of anti-PD-1 monoclonal 
antibody plus autologous dendritic cell-cytokine induced 
killer cell (DC-CIK) immunotherapy combined with 
hyperthermia in advanced malignant mesothelioma patients. 
As a nanoscale drug carrier, magnetosomes are easily 
functionalized by utilizing their magnetosome membrane in 
a number of ways. Firstly, directly loading the magnetosome 
surface with drugs using a number of cross-linking methods 
has demonstrated efficacy with single compounds. 
Doxorubicin linked to magnetosomes using glutaraldehyde, 
has demonstrated in vitro and in vivo antitumour properties 
against hepatocellular carcinoma [189]. In addition, cytosine 
arabinoside (Ara-C) for acute leukemia treatment has 
previously been cross-linked onto magnetosomes using 
genipin (a naturally derived, less toxic alternative to 
glutaraldehyde) to reduce the side effects and increase long-
term stability and release behaviours in circulation [190]. 
Strategies to increase the efficacy of drug-loaded 
magnetosomes has included co-delivery of combination 
therapies, successfully validating that cross-linkers can be 
used to couple two kinds of drugs with the magnetosome 
membrane. Combination of Ara-C with daunorubicin (DNR) 
was used to target acute myelogenous leukaemia (AML) 
with long-term release stability and minimized side effects 
[191] and more recently doxorubicin has been co-delivered 
with si-RNA [192]. These ample functional groups on the 
magnetosome membrane have also been exploited for 
conjugation of tumour-targeting peptides such as P75 for 
nanomolar affinity to EGFR and HER2 for specific detection 
of MDA-MB-468 and SKBR3 cells as well as xenograft 
tumors using MRI [193]. Secondly, the addition of extra 
polymeric coatings such as PLGA onto the magnetosome 
surface has been used to both enhance drug loading and 
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facilitate controlled drug release under certain conditions, for 
example pH [194]. Thirdly, magnetosomes can be 
manipulated genetically to express particular proteins on 
their surface including anti-HER2 affibodies (antibody 
mimemtics) for non-invasive imaging of tumours [195] or 
the expression of protein A in the membrane can conjugate 
antibodies directly [196]. Most promisingly, magnetosomes 
may help to overcome the issues surrounding nonspecific 
biodistribution of pharmaceuticals by utilizing their magnetic 
properties for magnetic targeting under the use of an external 
magnetic field. MTB bacteria themselves have been 
conjugated with drug-containing liposomes for delivery to 
hypoxic areas of tumours, notoriously difficult to access with 
conventional therapies. By utilizing the bacteria’s preference 
for low oxygen environments together with magnetic 
guidance, investigators were able to show up to 55% of MC-
1 bacterial cells penetrated into hypoxic regions of HCT116 
colorectal xenografts following a peritumoural injection and 
that the superior penetration depths were associated with 
active directional motility through magnetotaxis and 
aerotaxis of the MC-1 cells [197]. This technique has been 
adopted for administration of DNA plasmids for the 
generation of antigen-specific immunity. By combining 
human papillomavirus type E7 and Ig-Fc fragment (pSLC-
E7-Fc) with magnetosomes, Tang et al created a DNA 
vaccine for tumour immunotherapy generating antigen-
specific cytotoxic T lymphocyte activity with resultant 
tumour inhibition in a murine metastatic lung model 
(average pulmonary metastatic tumour weight of 343.6 mg 
vs 58.9mg) when administered with magnetic exposure 
[198]. The design of artificial antigen-presenting cells 
mimicking the characteristics of magnetosomes are also 
proving versatile agents for adoptive T-cell transfer to 
overcome the challenges associated with T-cell expansion 
and in vivo targeting. Persistent T cells in a murine 
lymphoma model were associated with tumour suppression 
brought about by a 78-fold ex-vivo expansion together with 
their magnetic enrichment [199]. This ability of 
magnetosomes to deliver therapies to target sites is relatively 
new within the field of immunotherapy, but is a promising 
strategy combining low systemic toxicity with superior non-
invasive targeting.  
4.5 Carbon nanomaterials 
As carbon is one of the most abundant elements in the 
known universe, and it only follows oxygen with regard to 
abundance in the human body, it could be considered as a 
suitable element for delivering medicine and other 
substances to the human body, especially at a cellular level. 
Furthermore, carbon nanomaterials have a large surface area 
that offers the possibility of multivalent conjugation of 
drugs/agents, thus explaining why several groups have 
recently tried to use carbon nanomaterials for improving 
immunotherapy efficacy [67,200]. In particular, carbon 
nanotubes (CNTs), that are cylindrical nanostructures made 
of carbon molecules, have been conjugated with tumour Ags 
with the aim of potentiating patients’ immune response 
against cancer. Indeed, Meng and colleagues showed that 
multi-wall CNTs can be conjugated with a tumour- cell 
vaccine (TCV), made of inactivated cancer cells and DCs 
that have been exposed to tumour Ags, and can enhance the 
efficacy of the vaccine in a murine model of liver cancer 
[201]. In another approach, single-wall CNTs have been 
used to increase the uptake of weak immunogenic peptides 
into DCs and macrophages. Furthermore, in vivo 
administration of the complexes promoted a specific T cell 
response [202]. Also, the addition of pathogen-associated 
molecular pattern (PAMP) agonists, such as CpG-ODNs, to 
functionalized CNTs has been shown to increase the TCV 
immunostimulatory properties. Moreover, the direct 
stimulation of T cells has been achieved by CNTs linkage 
with both peptide-loaded MHC-I and the co-stimulatory anti-
CD28 [200,203]. CNTs were also combined with polymeric 
NPs containing IL-2. The combined complex has been 
shown to be able to expand in vitro CD8+ T cells that in 
turn, upon in vivo administration, delayed tumour growth in 
a murine melanoma model [204]. CNTs have also been 
extensively studied for photothermal cancer therapy as they 
show strong absorbance in the NIR [67,205]. This feature 
allowed the Liu group to develop a combined therapy 
strategy: single-wall CNTs conjugation with anti-CTLA-4 
Abs enabled the achievement of photothermal tumour 
destruction together with anti-tumoural T cells infiltration, 
thus inhibiting cancer growth and metastasis in both murine 
melanoma and breast cancer models  [205]. Once again, 
therapy combination through the use of NPs seems to be a 
promising strategy in the fight against cancer. 
4.6 Virus-like nanoparticles 
Engineered virus-like particles (VLPs) resemble viruses, but 
are non-infectious because they contain no viral genetic 
material. The expression of viral structural proteins, such as 
envelope or capsid proteins, can result in the self-assembly 
of the VLPs. They can be engineered to display multiple 
epitopes or peptides in order to optimize their antigenicity 
and immunogenicity. Collectively, these unique 
characteristics of VLPs make them optimal cancer vaccine 
candidates [67,206]. For example, cowpea mosaic virus 
(CPMV), a plant virus that self-assembles into icosahedral 
shaped NPs, has been shown to interact with APCs. In 
particular, CPMV interacts with Vimentin expressed on 
APCs surface allowing virus entry into cells both in vitro and 
in vivo [207]. Furthermore, in another interesting study, 
Steinmentz and colleagues showed that CPMV VLPs could 
directly act on tumour cells by binding to Vimentin 
expressed on metastatic tumour cells [208]. In this context, 
Lizzotte et al. demonstated that the inhalation of CPMV NPs 
reduced established B16F10 lung melanoma metastasis and 
simultaneously activate neutrophils that can directly kill 
tumour cells or induce anti-tumour activity of T and NK 
cells [209]. Intratumoural administration of another kind of 
virus-like NPs significantly slowed down melanoma 
progression and prolonged survival of tumour bearing mice. 
Indeed, Lamarre group showed that the treatment with 
papaya mosaic virus (PapMV) NPs enhanced chemokine and 
pro-inflammatory cytokine production that, in turn, induced 
CD8+ T cell accumulation together with a concomitant 
decrease in MDSC presence within the tumour [210]. 
Finally, MelQbG10, a VLP loaded with A-type CpG-ODN 
has been tested in a phase IIa clinical trial in melanoma 
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patients (https://clinicaltrials.gov/ct2/show/NCT00651703) 
and it has been shown to trigger both effector and memory T 
cell responses [211]. 
5. Conclusions 
In the last few decades immunotherapy has become an 
emergent and promising approach to fight cancer in addition 
to conventional therapies. As result, several 
immunotherapeutic agents have been tested in clinical trials 
and then approved by the FDA/EMA. However, some 
limitations decrease the potential benefits of cancer 
immunotherapy including failure in patients with low 
quantity of TILs and also, immunotherapy is associated with 
toxicities due to drug accumulation in healthy tissues that 
causes an anomalous immune activation. Furthermore, the 
immunosuppressive TME can limit the efficacy of 
immunotherapy [124-128]. In order to overcome these 
problems, nanomedicine has been exploited to obtain several 
important advantages, such as tumour specific targeting and 
drug protection from its clearance in circulation. More 
importantly, NPs aim to decrease IRAEs and increase 
immunotherapy specific delivery. Furthermore, NPs can be 
modified in size, shape, immunogenicity, charge, surface 
alterations and can also be detected for medical imaging 
[10,67]. For this reason, a remarkable number of studies 
have been conducted recently to provide clear evidence that 
nanomedicine could have a significant impact in cancer 
immunotherapy. Although NP-based immunotherapy has 
shown excellent and promising results in preclinical studies, 
supporting the idea that it has an enormous potential for 
fighting cancer, to date, few strategies has been tested in 
clinical trials and none of them have been approved yet for 
clinical use [10]. Therefore, there is an urgent need to better 
clarify the interactions between nanomaterial properties and 
immune cells for a better design of the nanosystems. 
Similarly, we need to optimize nanoformulations and 
delivery systems that ensure low toxicities, high specificity, 
bio-availability and long-lasting efficacy. To achieve this 
purpose, it would be important to develop new 
methodologies that can minimize the variables in the 
production process and avoid NP- heterogeneity of size and 
shape, aggregation, endotoxin contamination or the presence 
of non-encapsulated drugs. In addition, the co-targeting by 
the use of NPs could be another possibility to strongly 
increase the efficacy of anti-cancer therapies. For instance, 
an NP-based delivery system loaded with an 
immunotherapeutic agent together with chemotherapy could 
overcome the problem of the acquired resistance to one of 
the two drugs. Similarly, NP loading with both 
immunotherapy and a drug that targets a TME stromal 
component could destroy the interactions between cancer 
cells and the surrounding microenvironment that have been 
shown to play important role in cancer development. 
Although it is really difficult to define the ideal NP for 
cancer immunotherapy, playing with NP features can allow 
us to find certain NP characteristics that must be successfully 
incorporated such that the encapsulated drug shows 
acceptable biocompatibility, targeting capacity and efficient 
activity in reducing tumour growth. As mentioned above, 
several types of NPs exist on the base of the material used 
for their formulation. Among them, certainly liposomes can 
be considered an ideal drug delivery system as they are 
composed of naturally occurring phospholipids, are 
biologically unreactive and indistinguishably immunogenic, 
thus possessing a low intrinsic toxicity. They are normally 
used for the transport of drugs because of their unique 
properties. Indeed, liposome composition strictly mimics the 
cell membranes allowing them to be easily internalized by 
cells through endocytosis or plasma membrane fusion. 
Moreover, a liposome possesses an aqueous core to 
encapsulate hydrophilic solutes that could not directly cross 
the cell membranes and a lipid bilayer to entrap hydrophobic 
substances, so that liposomes can carry both hydrophilic and 
hydrophobic drugs [142,143]. These features allow 
liposomes to be considered a valid solution for loading 
several drugs and thus for achieving the co-targeting of 
different components of the TME. For instance, the efficacy 
of Doxil (the liposome-encapsulated form of Doxorubicin) 
already approved for some kind of cancers [142-144], could 
be enhanced by the addition on the lipid bilayer surface of 
ICIs such as anti-PD-L1 or anti-CTLA/4 Abs (Figure 3). 
Furthermore, the presence of a dye such as Rhodamine B or 
Fluorescein embedded in the aqueous core or in the lipid 
bilayer could allow the in vivo tracking of liposomes for a 
better understanding of liposome/drug distributions in tissues 
and organs. In addition, liposomes could be modified in 
order to contain a polymeric matrix such as PLGA to better 
entrap the drug and maintain liposome shape. Moreover, 
exploiting PLGA immunogenicity we could induce DC 
maturation and therefore enhance immune responses 
[10,131]. On the other hand, the composition of our ideal NP 
strongly depends on several aspects such as the route of 
administration, the target and the loaded drug. If the aim is to 
prolong NP circulation time in blood, a possible strategy 
could be the addition of PEG on the surface of the NP: in 
fact, due to its immune-camouflage properties it escapes 
from the clearance by immune cells [130,212]. Importantly, 
hybrid lipid NPs made of phospholipids, PLGA and PEG on 
the outer layer, have shown targeting capacity and a selective 
uptake by pancreatic cancer cells when coupled with an anti-
CEA half-antibody compared to control NPs. [213,214]. 
Other important features to consider for our ideal NP are its 
size and charge: in fact, spherical NP diameter should be no 
more than 150 nm as bigger NPs activate the complement 
system and are easily removed from blood stream, 
accumulating in the spleen and the liver [214]. Defining NP 
ideal charge is quite difficult as this strongly depends on 
their route of administration: i.e. a positive charge is 
important to increase the attraction to the cell membrane that 
is negatively charged, however, cationic liposomes cannot be 
used for intravenous injection as they tend to aggregate and 
stick to each other. The ideal strategy is trying to find the 
best lipid formulation and ratio in order to obtain a NP able 
to interact with cells without generating sticky aggregates 
that are extremely dangerous, especially in the blood stream.                
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This “perfect” drug delivery system we have described gives 
only a general idea of the features that the ideal NP should 
have for the delivery of immunotherapeutic agents; however, 
as mentioned above, there is no “perfect” NP as its 
characteristics strongly depend on its application, route of 
administration, targeting tissue and the loaded drugs. Thus, 
only if we consider all these aspects we will be able to find 
the best NP features for a specific treatment and NP clinical 
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Figure 3. The ideal NP. The important components of a NP for cancer immunotherapy delivery include the choice of 
nanomaterial (e.g., lipids), targeting molecules/antibodies, the best size for avoiding NP clearance, the net charge for 
promoting cellular uptake and limit NP aggregation, the incorporation of a dye for NP tracking, the presence of PEG for 
increasing NP circulation time, the PLGA matrix for drugs incorporation. 
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